Results 71 to 80 of about 1,158 (177)

Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome [PDF]

open access: yes, 2015
OBJECTIVES: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS) requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed
Fujioka, K   +8 more
core   +1 more source

Intestinal and Multivisceral Transplantation: Where We Stand Today

open access: yesPediatric Transplantation, Volume 30, Issue 1, January 2026.
ABSTRACT Intestinal and multivisceral transplantation has evolved from an experimental to a life‐saving procedure for children and adults with complications of gut failure (GF). Suboptimal long‐term outcomes of transplant elicit recent advances in surgical and medical gut rehabilitation along with the introduction of glucagon‐like peptide‐2 (GLP‐2 ...
Mohamed Maklad   +5 more
wiley   +1 more source

Further improvement after 24-month treatment with teduglutide in a patient with active Crohn’s disease and short bowel syndrome

open access: yesThe Turkish Journal of Gastroenterology, 2018
Cite this article as: Borghini R, Caronna R, Corazziari ES, Picarelli A. Further improvement after 24-month treatment with teduglutide in a patient with active Crohn’s disease and short bowel syndrome. Turk J Gastroenterol 2018; 29: 250-1.
Raffaele Borghini   +3 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +206 more
wiley   +1 more source

Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria

open access: yes, 2020
BACKGROUND: Teduglutide use in pediatric patients with short bowel syndrome can aid in the achievement of enteral autonomy, but with a price of >$400,000 per y.
Raghu, Vikram Kalathur   +5 more
core   +1 more source

Development of dietetic staffing requirements for adult intestinal failure services using a best‐practice model

open access: yesNutrition in Clinical Practice, Volume 40, Issue 5, Page 1146-1157, October 2025.
Abstract Background The number of people diagnosed with chronic intestinal failure (CIF) worldwide is low. The condition is clinically complex to manage and resource intense. Guidance on best‐practice staffing levels is lacking. This paper proposes a methodology for determining dietetic staffing levels for adult CIF to estimate dietetic staffing levels
Sharon Carey   +2 more
wiley   +1 more source

Short bowel syndrome–associated intestinal failure patient experience: A mixed‐method study leveraging an online patient community

open access: yesNutrition in Clinical Practice, Volume 40, Issue 5, Page 1115-1124, October 2025.
Abstract Background Patients with short bowel syndrome–associated intestinal failure (SBS‐IF) require complex, personalized, and multidisciplinary care; however, there are disparities in access. This study measured the impact of unmet needs and treatment burden among patients and their caregivers.
Brian Po‐Han Chen   +6 more
wiley   +1 more source

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure [PDF]

open access: yes, 2018
Background & Aims: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and ...
Seidner, Douglas L.   +9 more
core   +1 more source

Real-world experience of Teduglutide use in adults with short bowel syndrome: a seven-year international multicenter survey [PDF]

open access: yes
International audienceBackground and aim: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal ...
Lamprecht, Georg   +76 more
core   +1 more source

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals

open access: yes
Background: This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support ...
Slobodan Milicevic   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy